Max Dahl
Analyst, Goldman Sachs
Replay available
BioArctic AB (STO: BIOA_B) Q2 2026 earnings conference call, held 2026-08-26. Replay captured from the company's public earnings webcast.

Analyst, Goldman Sachs
Analyst, RX Securities
Analyst, Nordia
CFO
Chief R&D Officer
Chief Commercial Officer
CEO
Watch the replay and follow the connected company analysis, news, and investor updates for Bioarctic Ab Class B.
WEBVTT NOTE Transcription provided by Deepgram Request Id: 01a03f56-d083-7620-a12a-c5e7cd8c8e26 Created: 2026-08-26T18:30:52.150Z Duration: 2369.016 Channels: 1 00:00:01.360 -- 00:00:03.679 Thank you so much, and good morning, and 00:00:03.679 -- 00:00:06.480 welcome to BioArctic's presentation for the second quarter 00:00:06.480 -- 00:00:07.840 of twenty twenty six. 00:00:08.800 -- 00:00:12.320 Leukembi continues to progress really well with new 00:00:12.320 -- 00:00:13.679 approvals and launches. 00:00:14.495 -- 00:00:15.775 And BioArctic 00:00:15.775 -- 00:00:18.735 has signed additional strategic partnerships, 00:00:18.735 -- 00:00:20.175 and we will talk more about this in 00:00:20.175 -- 00:00:22.575 today's webcast. Next slide, please. 00:00:24.015 -- 00:00:26.735 BioArctic is listed at nastax.comlargecap, 00:00:26.735 -- 00:00:28.975 and this is our disclaimer. Next slide, please. 00:00:29.820 -- 00:00:32.540 I'm Gunilla Osvald, the CEO of BIOAARTIK, and 00:00:32.540 -- 00:00:35.260 I will share today's presentation with our CFO, 00:00:35.260 -- 00:00:37.420 Anders Martin Leung and our Chief R and 00:00:37.420 -- 00:00:40.059 D Officer, Johanna Felting and our Chief Commercial 00:00:40.059 -- 00:00:41.900 Officer, Anna Kayagranblad. 00:00:41.980 -- 00:00:42.940 Next slide, please. 00:00:44.435 -- 00:00:46.595 I will start our presentation by giving some 00:00:46.595 -- 00:00:48.835 key highlights. Next slide, please. 00:00:49.875 -- 00:00:50.754 BIOAARTIQ 00:00:50.754 -- 00:00:51.555 is 00:00:51.555 -- 00:00:54.595 among world leaders in two different areas. 00:00:55.155 -- 00:00:56.835 The first one is, 00:00:57.555 -- 00:00:59.875 regarding highly selective antibodies 00:01:00.460 -- 00:01:01.820 where we are 00:01:02.380 -- 00:01:04.620 innovative and we a...